101645-12-9

Usage

Uses

Used in Pharmaceutical Synthesis:
Benzenamine, 4-[2-(4-pyridinyl)ethenyl]-, (E)is used as a key intermediate in the synthesis of pharmaceutical drugs, contributing to the development of new medications with diverse therapeutic applications.
Used in Organic Compound Synthesis:
Benzenamine, 4-[2-(4-pyridinyl)ethenyl]-, (E)is utilized as a building block in the creation of a variety of organic compounds, expanding the scope of chemical research and innovation.
Used in Research and Development:
Benzenamine, 4-[2-(4-pyridinyl)ethenyl]-, (E)is employed in research and development for the exploration of new materials and chemical processes, driving advancements in the chemical industry.
Used in Medical and Pharmacological Applications:
Due to its unique structural features and properties, Benzenamine, 4-[2-(4-pyridinyl)ethenyl]-, (E)may have potential uses in the medical and pharmacological fields, although further research is necessary to fully understand its capabilities and limitations in these areas.

Upstream product

• 1023-66-1 4-[(E)-2-(4-nitrophenyl)ethenyl]pyridine 
• 100-43-6 4-vinylpyridine 
• 106-40-1 4-bromo-aniline 
• 108-89-4 picoline 
• 555-16-8 4-nitrobenzaldehdye 

Downstream Products

• 101625-77-8 N-[4-((E)-2-Pyridin-4-yl-vinyl)-phenyl]-oxalamic acid ethyl ester 
• 139619-06-0 trans-4-pyridine 
• 139619-03-7 1-methyl-4-pyridinium iodide 
• 139619-05-9 trans-4-pyridine 
• 101625-78-9 Sodium; [4-((E)-2-pyridin-4-yl-vinyl)-phenylcarbamoyl]-methanoate 

Relevant academic research and scientific papers

A small-molecule chemosensor for the selective detection of 2,4,6-trinitrophenol (TNP)

A pyridine-based small-molecule receptor (L) for the specific recognition of TNP was synthesised and characterised by 1H NMR, 13C NMR and FT-IR spectra, and the optical properties were studied by UV-Vis absorption and PL spectra. The

ALPHA-SYNUCLEIN LIGANDS

The present invention generally relates to various compounds that are useful as α-synuclein ligands. The invention further relates to methods of using these compounds and their radiolabeled analogs for the detection of synucleinopathies, including Parkinson's disease (PD).

Inhibitory effect of cytotoxic nitrogen-containing heterocyclic stilbene analogues on VEGF protein secretion and VEGF, hTERT and c-Myc gene expression

A group of 21 nitrogen-containing heterocyclic stilbene derivatives, prepared by means of Heck coupling reactions, has been investigated for their cytotoxicity as well as their ability to inhibit the production of the vascular endothelial growth factor (VEGF) and the activation of telomerase. The ability of these compounds to inhibit proliferation of two tumoral cell lines (HT-29 and MCF-7) and one non-tumoral cell line (HEK-293) was first determined. Subsequently, we determined the capacity of the compounds to inhibit the secretion of VEGF in the aforementioned cell lines and downregulate the expression of the VEGF, hTERT and c-Myc genes, of which the latter two are involved in controlling the activation of telomerase.

Heterocyclic ethenyloxanilates as orally active antiallergic agents

Ethyl p-(pyrimidin-4-ylethenyl)oxanilate 2 and many substituted derivatives were found to have oral activity in the PCA assay. The pyrimidine moiety was replaced by other heterocycles but only pyrazine and pyridazine retained activity.